@article{oai:showa.repo.nii.ac.jp:00000498,
 author = {ANDO, Koichi and KUSUMOTO, Sojiro and TANAKA, Akihiko and YAMAOKA, Toshimitsu and OHMORI, Tohru and OHNISHI, Tsukasa and INOUE, Shin and SAGARA, Hironori},
 issue = {4},
 journal = {The Showa University journal of medical sciences},
 month = {2017-12, 2019-07-26},
 note = {We comparatively assessed the overall efficacies of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy for previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer in Asians through a meta-analysis of relevant phase-3 trials. The primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS), respectively. Pooled estimates were calculated as hazard ratios (HRs) with 95% confidence intervals (CIs). Seven studies on EGFR-TKIs met the inclusion criteria for this study. The HRs and 95% CIs for OS and PFS for EGFR-TKIs, relative to chemotherapy, were 0.98 (0.77–1.24) and 0.32 (0.24–0.43), respectively. We found no difference in overall efficacy between EGFR-TKIs and chemotherapy in terms of OS, although the median PFS with EGFR-TKI was superior to that with chemotherapy among Asians with previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer (UMIN ID: UMIN28424).},
 pages = {435--443},
 title = {EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis},
 volume = {29},
 year = {}
}